Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
2022; BMJ; Volume: 81; Issue: 4 Linguagem: Inglês
10.1136/annrheumdis-2021-220873
ISSN1468-2060
AutoresMarc Corbera‐Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, Georgina Espígol‐Frigolé, Roberto Ríos‐Garcés, Javier Marco‐Hernández, Amanda Denuc, Farah Kamberović, Patricia Pérez‐Galán, Alexandra Joseph, Annalisa D’Andrea, Kent Bondensgaard, María C. Cid, John F. Paolini,
Tópico(s)Atherosclerosis and Cardiovascular Diseases
ResumoEffective and safe therapies are needed for the treatment of patients with giant cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage colony stimulating factor (GM-CSF) may play a role in promoting inflammation in GCA.
Referência(s)